Deals In Depth: March And April 2020
AstraZeneca and Silence Therapeutics entered a March alliance worth up to $4.08bn for the discovery and development of siRNA drugs for cardiovascular, renal, metabolic and respiratory diseases, while the top April deal was a $3.9bn tie up between Fate Therapeutics and Janssen for iPSC-derived cell-based cancer immunotherapies.
You may also be interested in...
Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
During Q3, biopharma merger and acquisition value reached $48.6bn and drew in $43bn in potential deal value (PDV) from alliances. Device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.